ライフサイエンスコーパス: topoisomerase I

1 ds be referred to as 'topological poisons of topoisomerase I'.

2 TATA-dependent transcription such as NC2 and Topoisomerase I.

3 induction by the covalent complex formed by topoisomerase I.

4 or by the formation of poly(ADP-ribosyl)ated topoisomerase I.

5 wn previously to act as poisons of human DNA topoisomerase I.

6 s negative DNA supercoils in the presence of topoisomerase I.

7 of ARF/topoisomerase I complex and DNA-bound topoisomerase I.

8 it RNA topoisomerase activity of E. coli DNA topoisomerase I.

9 in and amino acids of the active site of DNA topoisomerase I.

10 o subunits of DNA gyrase, whereas CT643 is a topoisomerase I.

11 n the C-terminal domains of Escherichia coli topoisomerase I.

12 st endogenous protein inhibitor specific for topoisomerase I.

13 Eukaryotic topo II, a type II topoisomerase, is a homodimeric enzyme that solves topol

14 se II, and BRD2 directly bound and activated topoisomerase I, a known restrainer of R-loops.

15 P and other nucleotides in the regulation of topoisomerase I activity in the presence of camptothecin

16 In addition, the described ligand displayed topoisomerase I activity inhibition and self-fluorescenc

17 the active site region of the mutant E. coli topoisomerase I activity shifted the pH for optimal acti

18 of RNAP convoy formation and is abrogated by topoisomerase I activity.

19 ting that these growth defects are caused by topoisomerase I activity.

20 osphorylation, a modification that regulates topoisomerase I activity.

21 somes with camptothecin (CPT)-stabilized DNA-Topoisomerase I adducts activates an ATR-dependent pathw

22 Covalent topoisomerase I and DNA gyrase complexes are converted i

23 ing this assay, we found that all the tested topoisomerase I and II (TOP1 and TOP2, respectively) poi

24 Inhibition of topoisomerase I and II by camptothecin and etoposide tre

25 mage, and DNA-protein cross-links (including topoisomerase I and II cleavable complexes) produce stal

26 ations together, our study demonstrates that topoisomerase I and II may catalyze distinct steps of HB

27 nduction of DNA cross-linking, inhibition of topoisomerase I and II, and cell-cycle arrest at the S-p

28 e of the protein-protein interaction between topoisomerase I and RNA polymerase during stress respons

29 The functional interaction between topoisomerase I and RNA polymerase has evolved independe

30 a distinct mechanism of interaction between topoisomerase I and RNA polymerase in Mycobacterium tube

31 characterized interaction between bacterial topoisomerase I and RNA polymerase.

32 consistent with negative feedback control of topoisomerase I and topoisomerase IV expression, which i

33 e evaluated for DNA binding propensities and topoisomerases I and II inhibition as part of their mech

34 Escherichia coli topoisomerases I and III (Topo I and Topo III) relax neg

35 Escherichia coli topoisomerases I and III can decatenate double-stranded

36 ve for anti-RNA polymerase I/III, 5 for anti-topoisomerase I, and 8 for anticentromere, and 4 were no

37 NA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter al

38 rican patients were more likely to have anti-topoisomerase I (anti-topo I), anti-U1 RNP, and anti-U3

39 era containing autoantibodies against either topoisomerase I (anti-topo I; n = 12), nucleolar protein

40 PB1 alleles using DNA obtained from 318 anti-topoisomerase I antibody-positive patients and 561 healt

41 Anti-topoisomerase I antibody-positive patients were more lik

42 These C-terminal domains of E. coli topoisomerase I are known to interact with RNA polymeras

43 nd Senataxin (SETX), or by the inhibition of topoisomerase I, are actively processed into DNA double-

44 from the 5' side of a nick generated by DNA topoisomerase I at a ribonucleoside monophosphate residu

45 f the DNA cleavage complex formed by type IA topoisomerases is bactericidal.

46 This topoisomerase is being pursued as a novel target for the

47 the widely expressed nuclear protein TOPORS (topoisomerase I-binding arginine/serine rich) are associ

48 We report mutations in the gene for topoisomerase I-binding RS protein (TOPORS) in patients

49 uding ubiquitin-conjugating enzyme 9 (Ubc9); topoisomerase I-binding, arginine/serine-rich, E3 ubiqui

50 YjhX inhibits only topoisomerase I but not topoisomerase III and IV in vitr

51 biomarkers such as carbonic anhydrase IX and topoisomerase I by immunohistochemistry show clear evide

52 sult in severely compromised enzymes and DNA topoisomerase I-camptothecin dependent lethality.

53 DNA ends, like camptothecin-induced trapped-topoisomerase I, can be mediated by TDP1, BRCA1, CtIP an

54 we report the structure of Escherichia coli topoisomerase I catalytic domain (residues 2-695) in cov

55 Sera were tested for autoantibodies against topoisomerase I, centromere, and RNA polymerase I/III by

56 rotein cross-links, which include stable DNA-topoisomerase I cleavable complexes.

57 ncluding CTP, UTP, and GTP, had no effect on topoisomerase I cleavage and religation activities in th

58 Accumulation of mutant topoisomerase I cleavage complex can lead to SOS inducti

59 single-stranded break associated with mutant topoisomerase I cleavage complex is converted to double-

60 cting Fe-S cluster formation protect against topoisomerase I cleavage complex-mediated cell killing.

61 onse following the accumulation of bacterial topoisomerase I cleavage complex.

62 ibited thymidylate synthase (TS) and trapped topoisomerase I cleavage complexes (Top1CCs), leading to

63 associated with a corresponding increase of topoisomerase I cleavage complexes and were further incr

64 SOS induction following topoisomerase I complex accumulation is significantly lo

65 d and decreased levels, respectively, of ARF/topoisomerase I complex and DNA-bound topoisomerase I.

66 predicted structural similarity to the human topoisomerase I core subdomains I and II (30-IXAla, 30-6

67 repair of substrates mimicking a 3'-blocked topoisomerase I covalent intermediate or an oxidative st

68 solved crystal structure of Escherichia coli topoisomerase I covalently linked to a single-stranded o

69 ogenic and/or lethal DNA damage in which the topoisomerase is covalently linked to the 3'- or 5'-term

70 , the release of torsional strain by type II topoisomerases is critical for converging replisomes to

71 rved in other previously available bacterial topoisomerase I crystal structures.

72 also results from the action of calf-thymus topoisomerase I (CT Topo I) on a native supercoiled DNA

73 In conclusion, mitochondrial topoisomerase I dampens mitochondrial transcription and

74 ation of covalent complexes formed by mutant topoisomerase I defective in DNA religation.

75 His(nuc)Ala (H182A) mutant actually induced topoisomerase I-dependent cytotoxicity and further enhan

76 Bacterial and archaeal topoisomerase I display selectivity for a cytosine base

77 rase I purified from camptothecin-stabilized topoisomerase I-DNA cleavage complexes in human breast c

78 2/3 chains formed on camptothecin-stabilized topoisomerase I-DNA cleavage complexes.

79 No SUMO-1 peptide was detected in human topoisomerase I-DNA cleavage complexes.

80 Camptothecin-stabilized topoisomerase I-DNA cleavage intermediates in mammalian

81 soquinoline 5 and topotecan (2) bound in the topoisomerase I-DNA covalent complex, as well as molecul

82 plays a major role in the repair of stalled topoisomerase I-DNA covalent complexes.

83 othecins kill mammalian cells by stabilizing topoisomerase I-DNA strand passing intermediates that ar

84 Mutations in topA, encoding topoisomerase I, do not suppress the aberrant positionin

85 The DNA topoisomerase I enzyme of Mycobacterium tuberculosis (Mt

86 NA binding domains to form diverse bacterial topoisomerase I enzymes that are highly efficient in the

87 features observed for MtTOP1 may allow these topoisomerase I enzymes to carry out physiological funct

88 Among bacterial topoisomerase I enzymes, a conserved methionine residue

89 significantly increased frequencies of anti-topoisomerase I, fibrillarin, and RNP autoantibodies com

90 in M. smegmatis competed with the endogenous topoisomerase I for protein-protein interactions with RN

91 hese mutants are defective in the removal of topoisomerase I from DNA.

92 The encounter of DNA replication forks with topoisomerase I-generated single-stranded DNA breaks res

93 ction, regions of the DNA polymerase and DNA topoisomerase I genes were amplified by PCR, sequenced a

94 ymerase I/III group, +13.4 years in the anti-topoisomerase I group, +11.1 years in the anticentromere

95 Escherichia coli topoisomerase I has an essential function in preventing

96 cal probe, we find that Escherichia coli DNA topoisomerase I has low RNA topoisomerase activity and t

97 OS-inducing mutants of Y. pestis and E. coli topoisomerase I have also been utilized as models to stu

98 l linkers, selective inhibitors of bacterial topoisomerase I, have been evaluated using bacterial cyt

99 topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e

100 increased in MCF7 cells upon treatment with topoisomerase I-II inhibitors.

101 arkedly inhibited in MCF7 and LNCaP cells by topoisomerase I-II inhibitors.

102 nitially hypersensitive to the inhibition of topoisomerase I/II and PARP, but acquire drug resistance

103 tance of liberating DNA termini from trapped topoisomerase is illustrated by the progressive neurodeg

104 is work, we have studied the requirement for topoisomerase I in B. subtilis.

105 The inhibitory role of topoisomerase I in mitochondrial transcription is striki

106 ingly different from the stimulatory role of topoisomerase I in nuclear transcription.

107 p3beta differs from that of Escherichia coli topoisomerase I in that the former but not the latter re

108 rDNA and clarifies a structural role of DNA topoisomerase I in the epigenetic regulation of rDNA, in

109 n the essentiality of the topA gene encoding topoisomerase I in the model bacterium Bacillus subtilis

110 ported to promote the religation activity of topoisomerase I in the presence of camptothecin by itsel

111 Deficiency or depletion of mitochondrial topoisomerase I increased mitochondrial transcripts, whe

112 in inducing gammaH2AX response and repairing topoisomerase I-induced DNA damage as an alternative pat

113 hen gyrase, the sole T. thermophilus type II topoisomerase, is inhibited, TtAgo allows the bacterium

114 ction by either transcription termination or topoisomerase I inhibition has been shown to increase pa

115 s a synergistic effect of MYC inhibition and topoisomerase I inhibition on anticancer activity.

116 ochondrial inhibitors, intracellular ROS, or topoisomerase I inhibition orchestrates an inflammatory

117 yl side chains display excellent E. coli DNA topoisomerase I inhibition properties with IC50 values <

118 n synthesized and their Escherichia coli DNA topoisomerase I inhibition, binding to B-DNA duplex, and

119 nt anticancer activity do not exhibit strong topoisomerase I inhibition, suggesting a separate mechan

120 RC stress response was also activated by the topoisomerase I inhibitor 7-ethyl-10-hydroxycamptothecin

121 circadian toxicity patterns of irinotecan, a topoisomerase I inhibitor active against colorectal canc

122 y, markedly enhanced the cytotoxicity of the topoisomerase I inhibitor camptothecin (CPT).

123 Although the topoisomerase I inhibitor camptothecin also activated AT

124 nd PRC2 exhibit synthetic sensitivity to the topoisomerase I inhibitor Camptothecin and accumulate ga

125 h clinically-relevant nanomolar doses of the Topoisomerase I inhibitor camptothecin, loss of WRN exon

126 ries, Abbott Park, IL), and the DNA-damaging topoisomerase I inhibitor camptothecin-11 (CPT-11) or SN

127 we examined cells treated with the specific topoisomerase I inhibitor camptothecin.

128 This system contains SN-38-a prodrug of the topoisomerase I inhibitor irinotecan.

129 ntibody, cleavable peptide-based linker, and topoisomerase I inhibitor payload.

130 , cleavable peptide-based linker, and potent topoisomerase I inhibitor payload.

131 HER2, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload.

132 ) mice are hypersensitive to camptothecin, a topoisomerase I inhibitor that causes DNA damage primari

133 anticancer agent camptothecin (CPT) is a DNA topoisomerase I inhibitor that causes fork collapse and

134 Topotecan (TPT) is a topoisomerase I inhibitor that undergoes reversible, pH-

135 reported that combining (131)I-MIBG with the topoisomerase I inhibitor topotecan induced long-term DN

136 R-Cas9 screens in cells treated with the DNA topoisomerase I inhibitor topotecan.

137 n the present studies, an indenoisoquinoline topoisomerase I inhibitor was conjugated to DUPA via a p

138 latform, the effect of an apoptotic inducer, topoisomerase I inhibitor, 7-ethyl-10-hydrocamptothecin

139 various replication inhibitors, including a topoisomerase I inhibitor, camptothecin (CPT).

140 ncer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamp

141 s synthesized by conjugating camptothecin, a topoisomerase I inhibitor, to our proprietary, 'clickabl

142 raction of a PARP inhibitor, ABT-888, with a topoisomerase I inhibitor, topotecan, in PBMCs, tumor, a

143 ant after treatment with camptothecin, a DNA topoisomerase I inhibitor.

144 Here we encapsulated the topoisomerase-I inhibitor SN-38 in polymeric nanoparticl

145 Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but

146 an pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposu

147 rtical neurons from mice, we identify twelve topoisomerase I inhibitors and four topoisomerase II inh

148 Two series of indenoisoquinoline topoisomerase I inhibitors have been prepared to investi

149 Indenoisoquinolines are human topoisomerase I inhibitors in clinical testing with impr

150 p synthesis of a series of clinically active topoisomerase I inhibitors such as NSC 314622, LMP-400,

151 Measurements with Gyrase and Topoisomerase I inhibitors suggest hindrance to escape s

152 Camptothecins are potent topoisomerase I inhibitors used to treat high-risk pedia

153 amage induced by chemotherapy drugs, such as topoisomerase I inhibitors, results in S and G2 phase ar

154 Moreover, they acted as topoisomerase I inhibitors.

155 myosin VI transcript were decreased only by topoisomerase I inhibitors.

156 as a strategy for enhancing the efficacy of topoisomerase I inhibitors.

157 The camptothecin (CPT) Top1 (topoisomerase I) inhibitors exert their anticancer activ

158 es with dual tyrosyl-DNA phosphodiesterase I-topoisomerase I inhibitory activity in one low molecular

159 und 14a was synthesized and found to possess topoisomerase I inhibitory activity that was slightly be

160 analogues for their MYC-inhibitory activity, topoisomerase I-inhibitory activity, and anticancer acti

161 topoisomerase I to demonstrate that the ARF/topoisomerase I interaction is regulated by topoisomeras

162 whether Top1mt, the vertebrate mitochondrial topoisomerase, is involved in this process, we studied l

163 Mitochondrial topoisomerase I is a genetically distinct mitochondria-d

164 Bacterial topoisomerase I is a potential target for discovery of n

165 Topoisomerase I is a vital enzyme that controls DNA topo

166 DNA topoisomerase I is an essential nuclear enzyme involved

167 ulation of the covalent complex of bacterial topoisomerase I is bactericidal.

168 An elevated level of topoisomerase I is found in many carcinomas, making it a

169 Bacterial topoisomerase I is required for preventing hypernegative

170 DNA topoisomerase I is required for the relaxation of negati

171 Bacterial DNA topoisomerase I is responsible for preventing the hyper-

172 hibited PARP-1/NAD-facilitated religation of topoisomerase I-linked DNA (TLD) in the presence of camp

173 tudy suggests that dual targeting of MYC and topoisomerase I may serve as a novel strategy for antica

174 Finally, intercalators enhance topoisomerase I-mediated cleavage of negatively supercoi

175 Sites of topoisomerase I-mediated DNA cleavage do not appear to b

176 hibition can modulate the capacity to repair topoisomerase I-mediated DNA damage in the clinic.

177 ancer drugs that act by increasing levels of topoisomerase I-mediated DNA scission.

178 d detect as little as 0.5 SUMO-1 residue per topoisomerase I molecule.

179 duce expression of the corresponding E. coli topoisomerase I mutant (EcTOP-D111N) encoded on a high-c

180 ients with SSc who are positive for anti-DNA topoisomerase I or anticentromere autoantibodies.

181 y itself through the direct interaction with topoisomerase I or by the formation of poly(ADP-ribosyl)

182 patients who had either circulating anti-DNA topoisomerase I (P=7.58x10(-17)/4.84x10(-16)) or anticen

183 of scleroderma induced by immunization with topoisomerase-I peptide-loaded dendritic cells, Mehta et

184 p14ARF (ARF) and topoisomerase I play central roles in cancer and have re

185 Human topoisomerase I plays an important role in removing posi

186 DDR evoked by the topoisomerase I poison topotecan remained unaffected by

187 boxylesterases (CE) to yield SN-38, a potent topoisomerase I poison.

188 eath after replication stress as a result of topoisomerase I poisoning.

189 to a protein that potentiates the effects of topoisomerase I poisons by binding to damaged DNA and pr

190 veliparib to enhance the cytotoxicity of the topoisomerase I poisons topotecan and camptothecin (CPT)

191 tivity plays a role in protecting cells from topoisomerase I poisons.

192 activity of genotoxic chemotherapy, such as topoisomerase I poisons.

193 es represent a new class of highly cytotoxic topoisomerase I poisons.

194 uted aromathecins as novel antiproliferative topoisomerase I poisons.

195 This could be due to the suppression of topoisomerase I poly(ADP-ribosyl)ation through the compe

196 endogenous ubiquitin-family modifications of topoisomerase I purified from camptothecin-stabilized to

197 insertions into the nuclear genome, and with topoisomerase I recognition sites.

198 Human topoisomerase I removes DNA supercoils by clamping a dup

199 A full length structure of E. coli topoisomerase I reported here shows how the C-terminal d

200 ximal to the active site tyrosine of type IA topoisomerases is required for the relaxation of superco

201 member of the conserved Type IA subfamily of topoisomerases, is required for the cell proliferation i

202 rine in Yersinia pestis and Escherichia coli topoisomerase I results in bacterial cell killing due to

203 /topoisomerase I interaction is regulated by topoisomerase I serine phosphorylation, a modification t

204 ants of Yersinia pestis and Escherichia coli topoisomerase I showed that DNA religation can be inhibi

205 sis of purified Y. pestis and E. coli mutant topoisomerase I showed that the Met to Arg substitution

206 bit Mg(2+) dependent religation by bacterial topoisomerase I specifically could be developed into use

207 A comparison of bacterial topoisomerase I structures showed that a conserved trans

208 of HIF-1alpha protein by UVC did not require topoisomerase I, suggesting a similar yet distinct mode

209 inhibitor, in combination with topotecan, a topoisomerase I-targeted agent, was carried out to deter

210 agent that produces oxidative DNA damage, or topoisomerase I-targeted drugs (camptothecin and a nonca

211 in vivo evaluation of the combination of DNA topoisomerase I-targeted drugs and mTOR kinase inhibitor

212 In this study, we found that DNA topoisomerase I-targeted drugs and mTOR kinase inhibitor

213 ing technique to rapidly identify eukaryotic topoisomerase I targeting agents.

214 Topoisomerase I targeting poisons may be particularly ef

215 mutations in ribonuclease H, senataxin, and topoisomerase I that resolve RNA-DNA hybrids lead to inc

216 rase III is a more efficient decatenase than topoisomerase I, the opposite is true for DNA relaxation

217 is important to characterize the ability of topoisomerase I to cleave positively supercoiled DNA.

218 er cell lines and purified recombinant human topoisomerase I to demonstrate that the ARF/topoisomeras

219 such as the 3'-phosphotyrosyl linkage of DNA topoisomerase I to DNA.

220 The method is based on genetic tagging of topoisomerase I to immobilize the enzyme on a solid surf

221 phodiesterase-1 protects cells from abortive topoisomerase I (Top1) activity by hydrolyzing the 3'-ph

222 These deletion events are dependent on DNA topoisomerase I (Top1) and are initiated by Top1 incisio

223 In the absence of both topoisomerase I (Top1) and topoisomerase II (Top2) activ

224 The DNA-relaxing enzyme topoisomerase I (Top1) can be inhibited by heterocyclic

225 ch as DNA replication and transcription, DNA topoisomerase I (Top1) catalyzes the relaxation of DNA s

226 In eukaryotes, DNA topoisomerase I (Top1) catalyzes the relaxation of super

227 Ribonuclease activity of topoisomerase I (Top1) causes DNA nicks bearing 2',3'-cy

228 tyrosyl bonds resulting from the trapping of topoisomerase I (Top1) cleavage complexes.

229 DNA topoisomerase I (TOP1) has an important role in maintain

230 Topoisomerase I (Top1) has been shown to be coupled with

231 The inhibition of DNA topoisomerase I (Top1) has proven to be a successful app

232 the repair of damaged DNA resulting from the topoisomerase I (Top1) inhibitor camptothecin and a vari

233 gically transported from the indolocarbazole topoisomerase I (Top1) inhibitor class to the indenoisoq

234 The topoisomerase I (TOP1) inhibitor irinotecan triggers cel

235 Camptothecin (CPT), a topoisomerase I (TOP1) inhibitor, exhibits anti-tumor ac

236 ives, topotecan and irinotecan, are specific topoisomerase I (Top1) inhibitors and potent anticancer

237 Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of a

238 Indenoisoquinoline topoisomerase I (Top1) inhibitors are a novel class of a

239 Novel topoisomerase I (Top1) inhibitors are in clinical develo

240 The compounds were designed as topoisomerase I (Top1) inhibitors based on the indenoiso

241 A series of 7-azaindenoisoquinoline topoisomerase I (Top1) inhibitors have been prepared to

242 Hydroxylated analogues of the anticancer topoisomerase I (Top1) inhibitors indotecan (LMP400) and

243 The aromathecin or "rosettacin" class of topoisomerase I (top1) inhibitors is effectively a "comp

244 e study of a series of azaindenoisoquinoline topoisomerase I (Top1) inhibitors is reported.

245 entify predictors of cancer cell response to topoisomerase I (Top1) inhibitors, a widely used class o

246 DNA interstrand cross-linking (ICL) agents, topoisomerase I (TOP1) inhibitors, and in Holliday junct

247 In search for a novel chemotype to develop topoisomerase I (Top1) inhibitors, the pyrazolo[1,5-a]qu

248 ave synthesized indenoisoquinolines as novel topoisomerase I (Top1) inhibitors.

249 The 7-azaindenoisoquinolines are cytotoxic topoisomerase I (Top1) inhibitors.

250 ntaining wild-type and mutant alleles of DNA topoisomerase I (TOP1) into the haploid yeast gene-disru

251 ccharomyces cerevisiae, become unstable when topoisomerase I (Top1) is disrupted.

252 Topoisomerase I (Top1) is known to relax DNA supercoilin

253 Such linkages form in vivo when topoisomerase I (Top1) processes DNA.

254 Topoisomerase I (Top1) regulates DNA supercoiling and is

255 Topoisomerase I (Top1) relaxes DNA supercoiling by formi

256 Topoisomerase I (Top1) resolves supercoils by nicking on

257 ow rapid recruitment, within minutes, of DNA topoisomerase I (TOP1) to a large cohort of AR-regulated

258 e-strand breaks (DSBs) in cells depleted for Topoisomerase I (Top1), an enzyme that relaxes DNA super

259 transcription-associated damage in yeast is Topoisomerase I (Top1), an enzyme that removes torsional

260 ngle CrA-PdG adduct can form crosslinks with topoisomerase I (Top1), both directly and indirectly.

261 by RNase H2-dependent excision repair or by topoisomerase I (Top1)-catalyzed cleavage.

262 ver, in a RNase H2 knock-out yeast strain, a topoisomerase I (Top1)-dependent mutator effect develops

263 Reversible topoisomerase I (Top1)-DNA cleavage complexes are the ke

264 Reversible topoisomerase I (Top1)-DNA cleavage complexes are the ke

265 lymerase II, Rpb1, in response to stabilized topoisomerase I (Top1)-DNA cleavage complexes.

266 ellular enzyme that repairs the irreversible topoisomerase I (Top1)-DNA complexes and confers chemoth

267 A phosphodiesterase I (TDP1) repairs stalled topoisomerase I (Top1)-DNA covalent complexes and has be

268 This type of linkage is found at stalled topoisomerase I (Top1)-DNA covalent complexes, and TDP1

269 ety and has been implicated in the repair of topoisomerase I (Top1)-DNA covalent complexes.

270 Base damage and topoisomerase I (Top1)-linked DNA breaks are abundant fo

271 s otherwise highly homologous to the nuclear topoisomerase I (Top1).

272 Mitochondrial topoisomerase I (TOP1MT) is a type IB topoisomerase enco

273 Mitochondrial topoisomerase I (Top1mt) is a type IB topoisomerase pres

274 n nuclei and mitochondria, and mitochondrial topoisomerase I (Top1mt) is the only DNA topoisomerase s

275 opoisomerase in vertebrates is mitochondrial topoisomerase I (Top1mt).

276 that mutations in the gene encoding for DNA topoisomerase I (topA) give rise to mutator phenotypes w

277 Escherichia coli topoisomerase I (TopA), a regulator of global and local

278 mary cellular target of YjhX was found to be topoisomerase I (TopA), inhibiting both DNA replication

279 the spatiotemporal recruitment of GFP-tagged topoisomerase I (TopI) to sites of localized DNA damage

280 Topoisomerase I (Topo I) and Topo II inhibitors can sele

281 to camptothecin (CPT), impaired CPT-induced topoisomerase I (Topo I) degradation and ubiquitination,

282 Using an NKX3.1 affinity column, we isolated topoisomerase I (Topo I) from a PC-3 prostate cancer cel

283 Human DNA topoisomerase I (topo I) is an essential mammalian enzym

284 Topoisomerase I (topo I) is required for the proper init

285 e results of a phase I clinical trial of the topoisomerase I (Topo I) poison CPT-11 followed by the c

286 sor, p14ARF (ARF) is a positive regulator of topoisomerase I (topo I), a central enzyme in DNA metabo

287 cancer drugs slow the religation step of DNA topoisomerase I (topo I).

288 nteraction between the C-terminal domains of topoisomerase I (TopoI-CTDs) and the beta' subunit of RN

289 Presently it is shown that in addition to topoisomerase I, topopyrones A-D also act as poisons of

290 Promoter analysis showed that each topoisomerase is transcribed from its own operon by the

291 Acute depletion of mitochondrial topoisomerase I triggered neither a nuclear mito-biogeni

292 discrimination by prokaryotic and eukaryotic topoisomerases is vital to therapeutic utility, but is p

293 Mitochondrial topoisomerase I was co-immunoprecipitated with mitochond

294 herichia coli expressing SOS-inducing mutant topoisomerase I was utilized to demonstrate that covalen

295 titutions at the TOPRIM glycine of Y. pestis topoisomerase I were examined.

296 Mutants of recombinant Yersinia pestis topoisomerase I with hydrophobic substitutions at this p

297 oligonucleotides to Mycobacterium smegmatis topoisomerase I with progressive C-terminal deletions sh

298 The association of topoisomerase I with RNA polymerase during transcription

299 In depth biochemical analysis of E. coli topoisomerase I with the corresponding Arg-321 mutation

300 opy-number plasmid clones of Yersinia pestis topoisomerase I (YpTOP) with Asp-to-Asn substitution at

301 with arginine in recombinant Yersinia pestis topoisomerase I (YTOP) was the only substitution at this